Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo

Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo

These studies compared the efficacies of our clinical agent galeterone (Gal) and the FDA-approved prostate cancer drug, enzalutamide (ENZ) with two lead next generation galeterone analogs (NGGAs), VNPP414 and VNPP433-3β, using prostate cancer (PC) in vitro and in vivo models. Antitumor acti...

Full description

Bibliographic Details
Main Authors: Andrew K. Kwegyir-Afful, Senthilmurugan Ramalingam, Vidya P. Ramamurthy, Puranik Purushottamachar, Francis N. Murigi, Tadas S. Vasaitis, Weiliang Huang, Maureen A. Kane, Yuji Zhang, Nicholas Ambulos, Sudhir Tiwari, Pratima Srivastava, Ivo P. Nnane, Arif Hussain, Yun Qiu, David J. Weber, Vincent C. O. Njar
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Cancers
Subjects:
prostate cancer
castration-/drug-resistant pc cell
galeterone (gal)
nggas
vnpp433-3β ar/ar-v7
mnk1/2 degraders
mnk-eif4e/mtorc1 signaling pathways
apoptosis
Online Access:https://www.mdpi.com/2072-6694/11/11/1637

Similar Items

Similar Items